Psychedelic Pharmacist Association | Strategic Alliance Partners

Leaders of the newly launched Psychedelic Pharmacist Foundation discuss pharmacists' critical role in psychedelic-assisted therapy and patient education.

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

Engagement and recognition of pharmacist expertise grows as state psychedelic bills expand.

Although the committee's vote is non-binding, it does raise questions about optimal evaluation of psychedelics in clinical trials.

Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present.

The co-founders of PPA discuss the importance of advocacy work at this point in the development of the psychedelic medicine industry to help cement pharmacist’s role in the continuum of care.